ALAN H. AUERBACH
Chairman, Chief Executive and President
Alan Auerbach has been chairman, chief executive and president of Puma Biotechnology since the company was founded in 2011. The publicly traded biopharmaceutical company is dedicated to the acquisition and development of new treatments for cancer. The company focuses on in-licensing pharmaceutical candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then develops the drugs for commercial use. He was previously chief executive, president and board member of Cougar Biotechnology, the company he founded in 2003 and sold to Johnson & Johnson in 2009 for about $1 billion. He remained with Cougar as co-chairman of the Integration Steering Committee, a Johnson & Johnson unit that provided oversight for the development and commercialization of Cougar’s abiraterone acetate, which received approval for the treatment of metastatic prostate cancer in the United States and European Union in 2011. He also served as vice president, senior research analyst at Wells Fargo Securities, where he oversaw research coverage of small- and midsize capitalization biotechnology companies, focusing on those in the field of oncology. He also worked for Diagnostic Products Corporation, where he created clinical trials in the field of oncology.
For reprint and licensing requests for this article, CLICK HERE.
Stories You May Also Be Interested In
- LA 500: Alan H. Auerbach
- Cancer Drug Developer Puma Completes Funding Round
- Puma Biotechnology to Begin Trading Shares
- Positive Drug Trials Spur Healthy Investor Interest
- Maker of Cancer Drug Passes Test With Investors
- Investors Take Notice of Cancer Drug Company
- J & J; to Buy Cougar Biotechnology
- Trial Results Give Healthy Boost to Drug Maker